Craft

Karo Pharma

Stock Price

KR60.7

2022-11-24

Market Capitalization

KR13.6 B

2022-11-23

Revenue

KR3 B

FY, 2021

Karo Pharma Summary

Company Summary

Overview
Karo Pharma is a healthcare company, which develops and markets products for pharmacies and the health care sectors. The Company's development projects are focused on nuclear receptors as target proteins for the development of pharmaceuticals. Its products include medical compression socks, nutritional products, ergonomic products for people with disabilities, and medicine storage products. The Company also offers medicines for the treatment of sore throats, vaginal dryness, pains, etc. Its products under development include nuclear receptor RORgamma based products for the treatment of autoimmune diseases, compounds to treat multiple sclerosis and cancer, and a common cold spray.
Type
Public
Status
Active
Founded
1987
HQ
Stockholm, SE | view all locations
Website
https://karopharma.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Christoffer Lorenzen

    Christoffer Lorenzen, Chief Executive Officer

    • Jon Johnsson

      Jon Johnsson, Chief Financial Officer

      • Carl Lindgren

        Carl Lindgren, Vice President Business Development

        • Jonathan Kimber

          Jonathan Kimber, VP Operations

          LocationsView all

          2 locations detected

          • Stockholm, Stockholms län HQ

            Sweden

            Klara Norra kyrkogata 33

          • Stockholm, Stockholm County

            Sweden

          Karo Pharma Financials

          Summary Financials

          Revenue (H1, 2022)
          kr2.0B
          Gross profit (H1, 2022)
          kr1.5B
          Net income (H1, 2022)
          (kr140.6M)
          Cash (H1, 2022)
          kr353.1M
          EBIT (H1, 2022)
          kr3.8M
          Enterprise value
          $8.4B

          Footer menu